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Background: High fat feeding increases hepatic fat accumulation and is associated with hepatic insulin resistance.
AMP Activated Protein Kinase (AMPK) is thought to inhibit lipid synthesis by the acute inhibition of glycerol-3-
phosphate acyltransferase (GPAT) activity and transcriptional regulation via sterol regulatory element binding
protein-1c (SREBP-1c).
Methods: The purpose of this study was to determine if chronic activation of AMPK prevented an increase in GPAT1
activity in rats fed a high fat diet. Rats were fed a control (C), or a high fat (HF) diet (60% fat) for 6 weeks and injected
with saline or a daily aminoimidazole carboxamide ribnucleotide (AICAR) dose of 0.5 mg/g body weight.
Results: Chronic AMPK activation by AICAR injections resulted in a significant reduction in hepatic triglyceride
accumulation in both the C and HF fed animals (C, 5.5±0.7; C+AICAR, 2.7 ±0.3; HF, 21.8±3.3; and HF+AICAR,
8.0±1.8 mg/g liver). HF feeding caused an increase in total GPAT and GPAT1 activity, which was not affected by chronic
AMPK activation (GPAT1 activity vs. C, C+AICAR, 92±19%; HF, 186±43%; HF+AICAR, 234±62%). Markers of oxidative
capacity, including citrate synthase activity and cytochrome c abundance, were not affected by chronic AICAR
treatment. Interestingly, HF feeding caused a significant increase in long chain acyl-CoA dehydrogenase or LCAD
(up 66% from C), a marker of fatty acid oxidation capacity.
Conclusions: These results suggest that chronic AMPK activation limits hepatic triglyceride accumulation independent
of a reduction in total GPAT1 activity.
Keywords: AMPK, GPAT1, SREBP-1c, mTOR, LCADBackground
AMP-activated protein kinase (AMPK) is a major regula-
tor of energy homeostasis and nutrient metabolism.
AMPK is known to regulate fatty acid metabolism, protein
synthesis, and glucose uptake [1,2]. Furthermore, the acti-
vation of AMPK occurs by allosteric and covalent modifi-
cation of the enzyme in response to an energy deficit [3].
AMPK exerts its effects on energy metabolism by acutely* Correspondence: chad_hancock@byu.edu
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reproduction in any medium, provided the orregulating enzyme activity and protein abundance as well
as influencing transcription and translation of genes invol-
ved in energy metabolism [4-6]. For these reasons, AMPK
is of tremendous interest in understanding the mecha-
nisms involved in hepatic lipid accumulation.
Hepatic lipid accumulation occurs in conditions of
elevated dietary fat, obesity, and decreased metabolic
function associated with decreased liver function. There
are a number of mechanisms that could lead to increa-
sed hepatic lipid accumulation. Simply put, hepatic lipid
accumulation is the result of a greater amount of lipid
uptake and/or synthesis relative to lipid oxidation and
release into the circulation [7,8]. Non-alcoholic fatty liverral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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greater than five percent of liver weight in the absence of
excessive alcoholic intake [9]. Approximately 10-30 per-
cent of the adult population in the United States is
thought to have NAFLD, making it the most common
chronic liver condition among adults [10-17]. It has also
extended to adolescents with one study reporting approxi-
mately 61 percent of adolescent subjects with elevated
liver enzymes (a marker of NAFLD) being overweight or
obese, [18]. NAFLD is strongly associated with insulin
resistance and is the hepatic representation of metabolic
syndrome [9,11,19,20]. If not corrected, NAFLD can
lead to the development of non-alcoholic steatohepatitis
(NASH), cirrhosis of the liver and hepatocellular car-
cinoma [21].
Consistent with AMPK’s demonstrated role in energy
metabolism, AMPK has been reported to increase lipid
oxidation and inhibit lipid synthesis. One proposed
mechanism for AMPK induced lipid regulation is in the
acute inhibition of glycerol-3-phosphate acyltransferase
(GPAT), an integral enzyme in triglyceride accumulation.
GPAT is the rate-limiting enzyme catalyzing the first
committed step in triglyceride synthesis [22,23]. Of the
four predominant isoforms of GPAT, three are inhibited
by N-Ethylmaleimide (NEM). In contrast, the isoform
GPAT1 which is localized to the outer membrane of the
mitochondria is resistant to NEM and accounts for 10
percent of the total GPAT activity in extra-hepatic
tissues. In the liver, GPAT1 accounts for 30 to 50 percent
of the total GPAT activity, making it a significant contri-
butor to hepatic triglyceride regulation [24-26]. Chemical
activation of AMPK by an AMP-analog aminoimidazole
carboxamide ribonucleotide (AICAR) reduces fat accumu-
lation in the hepatocyte by decreasing GPAT1 activity by
30 to 40 percent [5,23,26]. It is also likely that AMPK
limits the fatty acid availability for triglyceride synthesis by
increasing fat oxidation rates. AMPK inhibits acetyl-CoA
carboxylase (ACC), an enzyme that catalyzes the forma-
tion of malonyl-CoA. Malonyl-CoA inhibits carnitine
palmitoyltransferase I (CPT1) resulting in decreased beta-
oxidation and increased fat synthesis. Decreasing malonyl-
CoA production results in an increase in CPT1 activity
[5,27-29]. Therefore, through AMPK’s acute role of inhi-
biting GPAT1 and increasing CPT1, there is an overall
increase in oxidation relative to triglyceride synthesis.
In addition to acute regulation of triglyceride synthesis
enzymes, recent evidence points to a role in which
AMPK influences the transcription and translation of
lipid synthesis enzymes [4,30]. Sterol regulatory element
binding protein-1c (SREBP-1c) increases the transcrip-
tion of lipid synthesis enzymes such as ACC, fatty acid
synthase (FAS), GPAT, and stearoyl-CoA desaturase
(SCD1) [13,31-34]. Previous work suggests that activa-
tion of AMPK decreases promoter activity of SREBP-1cin the liver cells, as well as decreasing the transcriptional
activity of liver X receptors (LCRa), an upstream tran-
scription factor and regulator of SREBP-1c expression,
thus decreasing SREBP-1c and LXR [4]. Further, AMPK
decreases SREBP-1c activity by interfering with the
mammalian target of rapamycin complex (mTOR) acti-
vity. The proposed mechanism for mTOR-dependent
activation of SREBP-1c is thought to be by cleavage of
the SREBP-1c molecule [35]. Other studies done using
cell culture models have shown that AMPK activation
can inhibit mitochondrial GPAT1 abundance by de-
creasing SREBP-1c activity [4,36]. Thus, in addition to
AMPK’s role as an acute regulator, AMPK may fur-
ther inhibit hepatic lipid accumulation by inhibiting
SREBP-1c through transcriptional regulation reduction
of mTOR activity.
While there is some evidence for AMPK dependent
inhibition of lipogenic enzymes [30,37], it is not com-
pletely understood how AMPK activation mediates this
effect in liver tissue. Furthermore, a greater understan-
ding of the role of AMPK activation in the process of
hepatic lipid accumulation is becoming increasingly
important due to the prevalence of NAFLD and NASH
as noted above. AMPK may be a valuable therapeutic
target for the treatment of these conditions. Therefore,
the purpose for this study was to examine the effects of
chronic activation of AMPK on enzymes critical for
hepatic triglyceride accumulation and lipid synthesis,
specifically ACC and GPAT1. This study was designed
to gain a greater understanding of the role of chronic
activation of AMPK on hepatic triglyceride synthesis
and accumulation.Materials and methods
Animal care
All procedures related to animal care and use were
approved by the Institutional Animal Care and Use
Committee of Brigham Young University.Diet
Male Wistar rats approximately 25 days old were divided
into 4 groups of 7-10 animals each. Two groups con-
sumed laboratory chow diet, 5053 PicoLab® Rodent Diet
20, and two groups consumed the high fat diet [38-40].
Food and water were provided ad libitum.
High Fat diet (g/kg of food):
116.3 g olive oil, 232.7 g flax seed oil, 87.2 g sugar,
174.6 g starch, 226.6 g casein, 4.5 g methionine, 30.7 g
gelatin, 51.2 g bran, 22.5 g vitamin mix (Harlan Teklad,
AIN76A), 52.2 g mineral mix (Harlan Teklad, AIN76),
1.4 g choline chloride. See Table 1 for the macronu-
trient composition of the two diets used in these
studies.
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A two-factor research design was used to examine the
effects of high fat feeding as well as AMPK activation on
factors important for the determination of fat accumula-
tion in liver tissue. See Table 2 for a complete descrip-
tion of control and treatment groups.
AICAR injections
AICAR was dissolved in 0.9% NaCl and administered
subcutaneously every morning for six weeks at a dose of
0.5 mg AICAR/g body weight. Rats were sacrificed
24 hours after the last injection was given. Throughout
the six weeks, rats from Control and High Fat groups
were handled daily and injected with a comparable
amount of saline at the time the AICAR groups received
AICAR injections.
Dissections
Rats were anesthetized with pentobarbital sodium
(65 mg/kg body weight.) Liver tissue was extracted once
rats were completely sedated. Liver was quickly removed
and clamp frozen with liquid nitrogen chilled metal
tongs then wrapped in aluminum foil and stored at -90
degrees Celsius.
Citrate synthase activity
As a measure of mitochondrial oxidative capacity, whole
tissue homogenate was used to measure citrate synthase
activity by the method of Srere [41]. Briefly, homoge-
nates were prepared in 175 mM KCl, 10 mM GSH,
2 mM Ethylenediaminetetraacetic acid (EDTA), pH 7.4
(100 mg of tissue per ml.) Homogenates were further
diluted in a solution of 100 mM Tris pH 8.0. Citrate
synthase activity was measured and recorded for each
sample.
Measurement of protein/enzyme abundance and
phosphorylation
Standard bicinchoninic acid (BCA) protein assays were
performed to determine protein concentration in theTable 2 Experimental design
Chow groups High fat groups
Chow + Daily Saline Injections High Fat (HF) + Daily Saline Injections
Chow + Daily AICAR Injections High Fat (HF) + Daily AICAR Injectionswhole tissue or membrane fraction homogenate. The
results were used to normalize protein content for
Western Blots and activity assays.
Standard Western blotting procedures were perfor-
med. Briefly, aliquots of the liver homogenates were
subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and then transferred to a
nitrocellulose membrane. The membrane was blocked
with 5% milk solution followed by incubation with the
primary antibody for the protein of choice overnight at 4
degrees Celsius. The next day, the membranes were
rinsed with Tris-Buffered Saline Tween-20 (TBST) and
incubated with the appropriate secondary antibody
dissolved in 1% milk in TBST for 1 hour. This was
followed again by rinses in TBST followed by one rinse
in TBS. Protein content was detected by chemilumines-
cence. Protein band densitometry was quantified and
analyzed with Image J and Alpha Ease software [4].
Primary antibodies for the following proteins were used:
Total AMPK (Cell Signaling; cat. No. 2532 L), phospho-
AMPK (Cell Signaling, Berveraly, MA; cat. No. 2535 L),
total ACC (GE Healthcare; cat. No. RPN1231V), SREBP-1c
(Santa Cruz, Santa Cruz, CA; cat. No. SC13551), mTOR
(Cell Signaling Technology Beverly, MA; cat. No. 2972 ).
In addition, we looked at 4E-binding protein (4E-BP)
(Cell Signaling Technology Beverly, MA; cat no. 9452)
and phosphor-raptor (Cell Signaling Technology Beverly,
MA; cat no. 2083) for indications of mTOR activity and
Cytochrome C (Santa Cruz, Santa Cruz, CA; cat. No.
sc-13156) and LCAD (a gift from Daniel P. Kelly) for an
indication of oxidative capacity.
Triglyceride assay
Liver triglycerides were measured according to the Folch
method. Forty to fifty milligrams of frozen liver were
homogenized with a 2:1 concentration of chloroform:
methanol and agitated in a cold room overnight at 4
degrees C. One ml of 0.9% NaCl was added to each
sample solution, vortexed and centrifuged for 1 hour at
1000 × g at 4 degrees C. The organic phase was removed
and dried down in a lyophilizer. Samples were recons-
tituted with 100 μl of Tert-Butanol Triton X solution.
Trigylceride content was then analyzed in each sample
with the WAKO triglyceride assay kit as per manufac-
turer’s instructions [42].
GPAT activity assay
The activity of microsomal and mitochondrial GPAT
was measured using the method described previously
[5,43,44]. Briefly, membrane fractions of liver tissue were
formed using sample homogenates prepared with 25 mg
of liver and homogenization buffer (250 mM Sucrose, 10
mMTrisHCl, 1 mM dithiothreitol (DTT), 1 mM EDTA,
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Figure 1 Phospho-AMP-activated protein kinase (pAMPK)
content in the liver was increased with acute 5-aminoimidazole-
4-carboxamide riboside (AICAR) treatment (n=5-7). Livers from
AICAR-treated rats were removed 1 hr after injection. Asterisk (*)
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Figure 2 Chronic activation of liver AMPK with daily injections
of AICAR limited the normal increase in triglyceride accumulation
that occurs with high fat feeding such that it was not significantly
different from the control group (n = 7-12). Letters are used to
represent significance; same letter means no significant difference
(P < 0.05). Graph represents means ± SE.
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the pellet reconstituted with 400 μl of the same homo-
genization buffer, aliquoted and frozen in -90 degree
Celsius freezer. Total GPAT activity was measured using
a cocktail of 800 μM [14C]glycerol 3-phosphate (G-3-P),
60 μM palmitoyl Co-A, 75 mM TrisHCl, 4 mM MgCl,
2 mg/ml BSA, 8 mM NaF, 1 Mm DTT, and non-labeled
G3P. Sample (40 μg protein) was added to the solution
incubated with and without 2 mM N-ethylmaleimide
(NEM), an inhibitor of microsomal GPAT to isolate and
measure the remaining activity, GPAT1 activity. The
reaction was run for 10 min at 37°C and stopped with
0.6 ml 1% HClO4 and chloroform-methanol (2:1). After
5 minutes on ice, another 1 ml of 1% perchloric acid
and 1 ml of chloroform was added to the solution. Sam-
ples were centrifuged for 1 hour at 1000 × g and washed
3 times with 1% perchloric acid after which 1 ml of
organic phase containing the labeled G-3-P incorporated
into lysophosphatidic acid was dried down using a lyo-
philizer. After reconstituting the samples with 2:1 tert-
butanol triton × solution, the sample with scintillation
fluid was placed into scintillation tubes and counts
measured with a scintillation counter. Subtracting the
mitochondrial GPAT (NEM-resistant) activity from the
total activity allowed for determining GPAT1’s activity
for each sample.
Statistical analysis
Significant differences between groups were determined
using two way analysis of variance (ANOVA) and
Bonferonni post hoc test for multiple comparisons. The
statistical software SigmaStat (Systat Software Inc, San
Jose, CA) was used. Statistical significance is defined at
p<0.05. Results are presented as means ± standard error
of mean (SEM).
Results
Chronic activation of AMPK limits hepatic triglyceride
accumulation
We have previously reported that rats given the same
treatment as in this study exhibit a significant main
effect of high fat feeding on increased circulating FFA’s
and abdominal fat accumulation [39]. In addition, this
duration of feeding as well as the dose and frequency of
AICAR treatment does not result in a significant in-
crease in body weight due to high fat feeding compared
to control fed rats [39]. However, as we expected,
chronic activation of AMPK using daily AICAR injec-
tions caused a reduction in hepatic triglyceride content.
We verified that the subcutaneous AICAR injections at
the dose we used (0.5 mg/g body weight) were sufficient
to cause activation of AMPK in the liver by measuring
AMPK phosphorylation one hour after acute subcutane-
ous injection in rats (see Figure 1). Chronic activation ofAMPK limited the normal increase in triglyceride accu-
mulation that occurs with high fat feeding such that it
was not significantly different from the control group
(See Figure 2). This finding is consistent with previous
reports on the effects of AMPK activation on fat accu-
mulation in the liver [45-47]. The mechanism by which
AMPK causes this reduction in a prolonged treatment of
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Figure 3 Total mammalian target of rapamycin complex
(mTOR) protein content of liver extracts revealed no significant
differences with high fat feeding or chronic AMPK activation
(n = 4-5). Bands for all 4 groups were taken side by side with no
interruption. Graph represents means ± SE.
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Chronic activation of AMPK decreased SREBP-1c in livers of
rats fed a high fat diet
Based on previous findings, chronic AMPK activation
would be expected to reduce transcription of GPAT via
inhibition of mTOR and SREBP-1c [4,35]. AMPK is
known to inhibit mTOR activity therefore we examined
mTOR, an mTOR regulatory protein (raptor), and a
downstream target of mTOR (4EBP) as an indication of
mTOR activity [48]. Western blots on total mTOR com-
plex protein in each group did not indicate a significant
difference between the groups (See Figure 3). As wouldFigure 4 Phospho-raptor content was increased in livers treated with
Graph represents means ± SE.be anticipated from the activation of AMPK, the total
levels of phospho-raptor were significantly increased
with chronic AMPK activation with both chow and high
fat feeding (See Figure 4). Phosphorylation of raptor on
(S792) by AMPK is important for mTOR inhibition
[49-51]. The total abundance of 4E-BP was significantly
increased with chronic AMPK activation with both the
chow and high fat feeding (See Figure 5a.) The phos-
phorylation state was determined by the shift in molecu-
lar weight of total 4E-BP protein (percentage of the total
protein in the two hypophosphorylated bands migrated
down 1-2 kDa compared to the total at molecular weight
of 20 kDa as previously documented) [48,52]. Consi-
dering the shift of 4EBP, our results indicate that there a
was lower amount of phosphorylated 4EBP following
chronic AICAR treatment compared to the control
group, which is consistent with the known inhibitory
effect of AMPK on mTOR activity (See Figure 5b).
AMPK plays a major role in the activity of SREBP-1c
in the liver by inhibiting mTOR complex activity [37].
SREBP-1c is positively regulated by mTOR and therefore
lipogenesis is upregulated with increased mTOR activity
[35]. We examined both forms of SREBP-1c in our
study: the full-length (inactive) form, and cleaved (active)
form [53]. High fat feeding caused a marked increase in
total full-length, uncleaved SREBP-1c abundance. Con-
sistent with the pattern observed in hepatic triglyceride
accumulation, chronic activation of AMPK caused a
reduction in the total full length, uncleaved SREBP-1c
abundance in rats fed either chow or high fat diet
(see Figure 6a). The cleaved SREBP-1c showed increases
with high fat feeding and decreases with chronic AMPK
activation as well but the differences were not as
pronounced (See Figure 6b). Therefore, our data indi-
cates that chronic activation of AMPK inhibits both full


















































Figure 5 Eukaryotic initiation factor 4E-binding protein (4EBP)
following HF and AICAR treatments. a. Total Eukaryotic initiation
factor 4E-binding protein (4EBP) results show an increase with the
treatment of AICAR (n = 4-5). Bands for all 4 groups were taken side by
side with no interruption Asterisk (*) denotes a main effect of AICAR
treatment (P<0.05). Graph represents means ± SE. b Eukaryotic initiation
factor 4E-binding protein (4EBP) phosphorylation (percentage of the
total protein in the 2 hypophosphorylated bands compared to total)
showed an increased phosphorylation with AICAR treatment (n = 4-5).
Bands for all 4 groups were taken side by side with no interruption.
Letters are used to represent significance; same letter means no
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Figure 6 Chronic activation of AMPK and sterol regulatory
element binding protein-1c (SREBP-1c). a. Chronic activation of
AMPK caused a reduction in the total abundance of uncleaved Sterol
regulatory element binding protein-1c (SREBP-1c) in rats fed either chow
or high fat diet (n = 3-5). Bands for all 4 groups were taken side by side
with no interruption. Letters are used to represent significance. A
significant main effect of AICAR was observed (p<0.05). Graph represents
means ± SE. b. Chronic activation of AMPK caused a reduction in the
total abundance of cleaved (65-68 kDa bands) SREBP-1c in the liver of
rats fed either chow or high fat diet (n = 4-5). Bands for all 4 groups
were taken side by side with no interruption. Letters are used to
represent significance. A significant main effect of AICAR and high fat
feeding was observed (p<0.05). Graph represents means ± SE.
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dependent response as seen with 4EBP phosphorylation.
Chronic activation of AMPK had no effect on GPAT1 activity
but a high fat feeding effect was present
Lipid synthesis enzymes increased by SREBP-1c include
ACC and GPAT. We first examined the abundance of
total ACC in response to high fat feeding and chronic
AMPK activation and found that AMPK activation
caused a significant reduction in total ACC protein in
the chow group. Interestingly, high fat feeding did not
produce a significant increase in total ACC protein (See
Figure 7). These results are consistent with cleaved
SREBP1-c total content.
GPAT1 activity was measured because it is another
lipogenic target of SREBP-1C and is a rate-limiting
enzyme for triglyceride synthesis [36]. High fat feeding
caused an increase in total and NEM-sensitive GPAT
activity in the liver (Figure 8a). Surprisingly, chronic
activation of AMPK in either control or high fat fed
animals did not cause a reduction in total or NEM-sensitive (GPAT1) activity (Figure 8b). Our results
present the novel finding that there is not a direct
correlation of chronic activation of AMPK with GPAT1
activity. We expected to see a reduction in GPAT1
activity based on previous results in hepatocytes regar-
ding the acute effect of AMPK on GPAT activity [5,26].
These findings prompted further exploration of the
mechanisms and regulation of fatty acid oxidation.
Lipid oxidation
Long chain acyl-CoA dehydrogenase (LCAD) was not
influenced by chronic AMPK activation but was increased
with high fat feeding
Hepatic lipid accumulation is a balance between the lipid
synthesis and oxidation so two markers of mitochondrial
oxidative capacity in the liver were measured. Neither
high fat feeding nor chronic activation of AMPK showed
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Figure 7 Total acetyl coA carboxylase (ACC) content had a
main effect of chronic AMPK activation (n = 7-10). High fat
feeding blunted the decrease in total ACC content with the HF +
AICAR group. Bands for all 4 groups were taken side by side with no
interruption. Letters are used to represent significance. Asterisk (*)
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Figure 8 GPAT activity following high fat feeding and AICAR
treatments. a. High fat feeding increased total glycerol-3-phosphate
acyl-transferase (GPAT) activity (n = 5-8) in liver. A main AICAR effect on
total GPAT activity was absent. Asterisk (*) denotes a main effect of high
fat feeding (P < 0.05). Graph represents means ± SE. b. High fat feeding
increased NEM-sensitive glycerol-3-phosphate acyl-transferase (GPAT1)
activity in liver (n = 5-8). A main AICAR effect on total GPAT activity




















Figure 9 Citrate synthase activity in the liver did not increase
with either high fat feeding or chronic AMPK activation (n = 4-5).
Graph represents means ± SE.
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content (data not shown) in the liver. Long chain acyl-
CoA dehydrogenase (LCAD), a key enzyme responsible
for the first step in the oxidation of long-chain fatty acyl-
CoAs was measured [54]. A significant increase in LCAD
was observed in response to high fat feeding, suggesting
greater capacity for fat oxidation (See Figure 10a). Inter-
estingly no effect was seen in the animals treated with
AICAR (See Figure 10b). These results suggest that
chronic AMPK activation does not play a significant role
in changing the oxidative capacity of liver content con-
trary to what has been found previously in skeletal muscle
[38,39,55]. Similar to the GPAT1 data, these results do not
account for the observed difference in hepatic triglyceride
levels in response to chronic AMPK activation.
Discussion
The purpose of this study was to examine a potential
mechanism by which chronic AMPK activation limits fat
accumulation in the liver. We hypothesized that AMPK
would cause a reduction in GPAT1 activity, a rate limit-
ing enzyme for triglyceride synthesis. GPAT1 has been
shown to be influential in the development of NAFLD
through its role in triglyceride synthesis in the liver and
when overexpressed leads to excess triglyceride synthesis
[22,26,56-58]. Neschen et al. and Hammond et al. dem-
onstrated that GPAT1 knockout mice had less triglyce-
ride accumulation when compared to wild type mice fed
a high fat diet [59,60]. AMPK is thought to inhibit the
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Figure 10 Long chain acyl CoA dehydrogenase (LCAD)
following high fat feeding and AICAR treatments. a. There was a
main high fat effect on total long chain acyl CoA dehydrogenase
(LCAD) content in the liver (n = 8-10). Asterisk (*) indicates a main
effect of high fat diet (P < 0.05). Graph represents means ± SE.
b. Chronic activation of AMPK did not have an effect on total long
chain acyl CoA dehydrogenase (LCAD) content in the liver (n = 4-5).
Bands for all 4 groups were taken side by side with no interruption.
Letters are used to represent significance; same letter means no
significant difference (P < 0.05). Graph represents means ± SE.
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for GPAT1 and other lipogenic enzymes [31-33]. In con-
trast to our hypothesis, we found that chronic AMPK
activation did not cause a reduction in GPAT1 activity
in either the control group or the animals receiving a
high fat diet. Therefore, results from this study suggest
that chronic AMPK activation limits triglyceride ac-
cumulation in the liver by a mechanism other than a
reduction in triglyceride synthesis capacity.
It is well documented that AMPK activation reduces
hepatic triglyceride accumulation [46,47]. However the
mechanisms responsible for this reduced triglyceride
content in the setting of high fat feeding are not fully
understood. AMPK has been best characterized as a
regulator of fatty acid oxidation [61]. AMPK affects an
increase in oxidation by inhibition of ACC [47]. In-
hibition of ACC results in less malonyl-CoA synthesis
leading to a greater activity of CPT1 due to reduced
inhibition by malonyl-CoA [28,61,62]. Recently, a greater
appreciation of AMPK as a regulator of triglyceride syn-
thesis has developed. Sterol regulatory element bindingprotein-1c (SREBP-1c) is a major regulator of lipogenic
enzymes and AMPK reduces SREBP-1c and downstream
lipogenic enzymes through an mTOR-dependent me-
chanism [4,47]. GPAT1 is one lipogenic enzyme that has
been clearly associated with an increase in triglyceride
synthesis and accumulation. The regulation of GPAT1
by SREBP-1c is evidenced by the 6.7-fold increase in
GPAT1 by an overexpression of SREBP-1c in adipocytes
[36]. Further, an expected increase in GPAT1 with re-
feeding does not occur in liver in the absence of SREBP-
1c [63]. Results from our study confirm that AMPK
activation leads to a reduction in SREBP-1c abundance.
Consistent with this reduction in SREBP-1c content, we
observed an AMPK dependent reduction in total ACC,
one of the enzymes positively regulated by SREBP-1c.
GPAT1 activity assay results were unexpected and
differed from the pattern observed with triglycerides,
SREBP-1c and ACC. Total and NEM-sensitive (GPAT1)
GPAT activity was increased with high fat feeding but
chronic AMPK activation did not appear to have an
inhibitory effect. Therefore our results in intact liver
with chronic AMPK activation suggest an alternative
regulation of total triglyceride synthesis capacity via
GPAT1 than has previously been proposed in isolated
hepatocytes with acute AMPK activation.
The regulation of SREBP-1c by AMPK is thought to
be dependent upon inhibition of mammalian target of
rapamycin (mTOR) and transcriptional activity of liver
X receptor (LXR) and SREBP-1c [4,35,64]. SREBP-1c is
significantly decreased by inhibitors of mTOR such as
rapamycin. [65]. This indicates that through AMPK’s
inhibition of mTOR activity, AMPK has the effect of
reducing SREBP-1c activity Further, AMPK’s role in
reducing mTOR activity results in decreased protein
synthesis in liver tissue [48]. The mechanism by which
AMPK decreases mTOR activity was proposed by Inoki
et al. to be by phosphorylation and activation of an
upstream protein in the signaling cascade, tuberous
sclerosis complex 1/2 (TSC1/2) [66,67]. mTOR phos-
phorylates downstream proteins such as eukaryotic
translation initiation factor 4E-binding protein (4E-BP)
and ribosomal protein p70 S6 (S6K1) thereby increasing
translation of various proteins and overall protein syn-
thesis [48,68]. Therefore, we can get an indication of the
effect of chronic AMPK activation on mTOR activity by
measuring the phosphorylation state (or shift) of 4E-BP
[48,52]. Our study validated the effect of AMPK activa-
tion in the liver by showing a decrease in phosphorylated
4E-BP (increased hypophosphorylation) in the AICAR
treated groups [52]. This suggests an inhibition of
mTOR activity and explanation for the pattern seen in
the SREBP-1c results.
Triglycerides accumulate in the liver particularly with
chronic high fat feeding through an up-regulation of
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ride synthesis and greater inhibition of CPT-1, a major
regulator of beta-oxidation. This is evidenced by a
marked decrease in beta oxidation when GPAT1 is
overexpressed in hepatocytes [56,58,69] and increased
beta oxidation markers when GPAT1 is knocked out in
mouse myocytes [59]. There is clear evidence that a
chronic high fat diet results in significantly higher hep-
atic weights and triglyceride levels [8,70,71]. Our study
duplicated such results with an increase in triglycerides
after prolonged high fat feeding. In accordance with
reported results of AMPK activation in cultured hepato-
cyte models [45,72], the chronic AICAR treated intact
liver tissue in our study had reduced levels of trigly-
cerides in the liver to control levels. AMPK activation
inhibits triglyceride accumulation by increasing beta
oxidation in the cell [47,73] as well as in its proposed
inhibition of mTOR and downstream targets such as
SREBP-1c as noted above [67,74]. These mechanisms
could explain the fat accumulation with high fat feeding
and reductions with chronic AICAR treatment in the
livers that was seen in our triglyceride assay results.
Therefore, the reduction seen in triglyceride accumula-
tion with chronic AMPK activation was consistent with
what was expected.
Increased fat oxidation with high fat feeding could be
another contributing factor to explain the conflicting
findings of triglyceride content and GPAT1 data in our
study. High fat states, such as ob/ob models, have shown
an increase oxidative capacity with a simultaneous in-
crease in fatty acid oxidation [75]. This high fat effect on
fatty acid oxidative capacity gave reason for measuring
LCAD, a marker of fatty acid oxidative capacity. Further,
AMPK activation is known to influence mitochondrial
biogenesis in both skeletal muscle [38,39,55] and in adi-
pose tissue [76]. Interestingly, we did not see an increase
in either citrate synthase activity or cytochrome c con-
tent with either high fat feeding or chronic activation of
AMPK in the liver. However, a significant increase of
LCAD with high fat feeding was observed. The increase
seen in LCAD is consistent with the high fat effect
expected but the chronic AMPK activation effect was
not apparent from the data. Therefore, the issue of how
the chronic effects of AMPK activation lead to a
decrease in hepatic triglyceride accumulation remains to
be resolved.
It is important to note some of the limitations in our
study. First, our study did not investigate the acute
regulation of GPAT by AMPK noted in other studies.
AMPK has been shown to have an acute inhibitory effect
on GPAT1 activity as shown in previous studies, which
is likely due to phosphorylation of GPAT1 [5,24,26,77].
This acute effect was not the focus of our study, and it is
not known whether this played a factor in overall trigly-ceride accumulation. The reduction in triglycerides
could be explained solely by the acute inhibition of
GPAT by AMPK. Second, the fat in the high fat diet
used in this study was composed of olive oil and flaxseed
oil and was not a typical composition for a high diet
(see Methods) due to use of tissues from animals in a
companion study. This may influence fat accumulation
patterns seen in our study and/or responsiveness to
AMPK. Therefore more work could be done to see if
our results in the chronic setting were unique to the
type of fat used in our study.
Conclusions
Given the current trends in lifestyle and dietary habits,
the prevalence of NAFLD and the development of
NASH are likely to continue to increase. AMPK is
widely recognized as a central regulator/sensor of cel-
lular energy metabolism and when activated, is known
to limit hepatic fat accumulation. Thus, AMPK is an
attractive target for potential therapeutic interventions
designed to treat excess fat accumulation in the liver.
In this study we examined the effect of chronic activa-
tion of AMPK via systemic administration of AICAR on
hepatic GPAT1 activity. High fat feeding resulted in
increased hepatic GPAT1 activity while chronic AICAR
administration had no effect on GPAT1 activity over
time. This was in contrast to the clear effect of AICAR
treatment on triglyceride content and transcriptional
regulation in the liver. Further areas of interest that may
help explain our findings include research on the role of
AMPK activation and other lipid regulatory mechanisms
such as cellular uptake or release of fatty acids and other
lipid molecules.
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